• Wed. Sep 30th, 2020

Addictions

  • Home
  • FDA’s Ok to Roche’s Oral SMA Therapy; Roche’s Etrolizumab Mixed Results in Ulcerative Colitis; Secura receives rights to Copiktra from Verastem

FDA’s Ok to Roche’s Oral SMA Therapy; Roche’s Etrolizumab Mixed Results in Ulcerative Colitis; Secura receives rights to Copiktra from Verastem

Roche Set to Compete With Biogen and Novartis in the SMA Market With its First Oral Therapy  The US FDA has recommended the use of Evrysdi (risdiplam), a candidate of…

Drug Wars and Racism in Foster Care

It’s as if everything the drug war touches is corrupted or destroyed. The U.S. child foster care system is no exception. From 2000 to 2011, researchers estimate one third of…

Celiac Disease: The Hidden Epidemic of Gluten Sensitivity

The contribution of key pharma companies, such as 9 Meters Biopharma, ImmunogenX, Provention Bio, Cour Pharmaceuticals/Takeda, Precigen ActoBio, Falk Pharma, and Zedira is significant in driving Celiac disease market size.…

Hedonism and Weed Leads to Happiness

Sharp legal and social distinctions are often made between medicinal and recreational marijuana, with indistinguishable recreational marijuana typically having a dark cloud cast over it. Why the distinction? At universities…

Sanofi acquires Principia; FDA’s Nod to Roche’s Enspryng; BMS, Dragonfly’s Licensing Deal

New strategy, new outlook: Sanofi takes another step, gains full control over the Principia’s MS treatment  Sanofi has inked a definitive agreement with Principia Biopharma to acquire the company, all…